Trial Profile

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Capecitabine; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Liver cancer; Lung cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms VALUE-CHECK

Most Recent Events

10 Jan 2025 Status changed from not yet recruiting to recruiting.
24 Jul 2024 Planned number of patients changed from 310 to 360.
24 Jul 2024 Planned initiation date changed from 1 Jul 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com